Epoxomicin[1] | |
---|---|
(2S,3S)-N-((2S,3R)-3-hydroxy-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxobutan-2-yl)-3-methyl-2-((2S,3S)-3-methyl-2-(N-methylacetamido)pentanamido)pentanamide |
|
Other names
BU 4061T |
|
Identifiers | |
CAS number | 134381-21-8 |
PubChem | 3035402 |
ChEMBL | CHEMBL207990 |
Jmol-3D images | Image 1 |
|
|
Properties | |
Molecular formula | C28H50N4O7 |
Molar mass | 554.72 g mol−1 |
Appearance | White solid |
Solubility in DMSO | 10 mg/mL |
(verify) (what is: / ?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
Infobox references |
Epoxomicin is a naturally occurring selective proteasome inhibitor with anti-inflammatory activity.[2] It was originally discovered in 1992.[3] Injected, it can induce Parkinson's-like symptoms in rats.
Derivatives of epoxomicin include carfilzomib.